Pre-conditioning Modifies the Tumor Microenvironment to Enhance Solid Tumor CAR T Cell Efficacy and Endogenous Immunity
Preprint
Abstract
Chimeric antigen receptor (CAR) T cell therapy has led to impressive clinical responses in patients with hematological malignancies; however, its utility in patients with solid tumors has been limited. While CAR T cells for the treatment of advanced prostate cancer are being clinically evaluated and are anticipated to show bioactivity, their safety and the impact of the immunosuppressive tumor microenvironment (TME) have not been faithfully explored preclinically. Using a novel human prostate stem cell antigen knock-in (hPSCA-KI) immunocompetent mouse model and syngeneic murine PSCA CAR T cells, we performed analyses of normal and tumor tissues by flow cytometry, immunohistochemistry, and/or RNA sequencing. We further assessed the beneficial impact of cyclophosphamide (Cy) pre-conditioning on modifications to the immunosuppressive TME and impact on PSCA-CAR T cell safety and efficacy. We observed an in vivo requirement of Cy pre-conditioning in uncovering the efficacy of PSCA-CAR T cells in prostate and pancreas cancer models, with no observed toxicities in normal tissues with endogenous PSCA expression. This combination also dampened the immunosuppressive TME, generated pro-inflammatory myeloid and T cell signatures in tumors, and enhanced the recruitment of antigen-presenting cells, and endogenous as well as adoptively-transferred CAR T cells, resulting in long-term anti-tumor immunity.Keywords
All Related Versions
- Published version: Molecular Therapy, 29 (7), 2335.
This publication has 49 references indexed in Scilit:
- Software for Computing and Annotating Genomic RangesPLOS Computational Biology, 2013
- Engineered T cells for pancreatic cancer treatmentHPB, 2011
- Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cellsBlood, 2010
- Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell eliminationCancer Immunology, Immunotherapy, 2009
- Mapping and quantifying mammalian transcriptomes by RNA-SeqNature Methods, 2008
- Cyclophosphamide Enhances the Antitumor Efficacy of Adoptively Transferred Immune Cells through the Induction of Cytokine Expression, B-Cell and T-Cell Homeostatic Proliferation, and Specific Tumor InfiltrationClinical Cancer Research, 2007
- Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go?Nature Clinical Practice Oncology, 2006
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamideBlood, 2005
- The hinge region of the CD8α chain: structure, antigenicity, and utility in expression of immunoglobulin superfamily domainsInternational Immunology, 1992